Nach Genre filtern
- 91 - Thyroid Eye Disease: Your Questions Answered With Drs. Prem Subramanian and Mark DinkinWed, 17 Apr 2024 - 14min
- 90 - Thyroid Eye Disease: Treatment and Monitoring With Drs. Prem Subramanian and Mark DinkinWed, 17 Apr 2024 - 12min
- 89 - Thyroid Eye Disease: Screening and Diagnosis With Drs. Prem Subramanian and Madhura TamhankarWed, 17 Apr 2024 - 14min
- 88 - Current and Emerging Gene Therapies for IRDs With Drs. Christine Kay and Lejla VajzovicMon, 08 Jan 2024 - 14min
- 87 - Genetic Testing and Counseling for IRDs With Drs. Lejla Vajzovic, Christine Kay, and Rachelle LinMon, 08 Jan 2024 - 17min
- 86 - IRDs: Improving Patient Workup With Drs. Lejla Vajzovic, Christine Kay, and Rachelle LinMon, 08 Jan 2024 - 16min
- 85 - Thyroid Eye Disease 360˚: Trends in Research and Novel Target Pathways With Drs. Andrea Lora Kossler and Prem SubramanianSun, 31 Dec 2023 - 22min
- 84 - Thyroid Eye Disease 360˚: Conventional and Novel Surgical Trends With Drs. Raymond Douglas and Roger DaileySun, 31 Dec 2023 - 16min
- 83 - Thyroid Eye Disease 360˚: Balancing Benefits and Risks of IGF1-R Therapy With Drs. Raymond Douglas and Andrea Lora KosslerSun, 31 Dec 2023 - 16min
- 82 - Thyroid Eye Disease 360˚: Medical Trends in Treatment With Drs. Raymond Douglas and Ana Carolina VictoriaSun, 31 Dec 2023 - 17min
- 81 - Visionary Viewpoints in Cataract & Refractive Surgery: The Future of Refractive Surgery With Drs. Dagny Zhu and George Waring IVFri, 29 Dec 2023 - 22min
- 80 - The Retina Radar With Dr. Arshad Khanani: DME With Dr. Diana DoTue, 12 Dec 2023 - 24min
- 79 - Visionary Viewpoints in Cataract & Refractive Surgery: Advances in Diagnostics & Guidance Systems With Drs. Dagny Zhu and Nicole FramFri, 15 Dec 2023 - 20min
- 78 - Visionary Viewpoints in Cataract & Refractive Surgery: Navigating Advances in Biometry & IOL With Drs. Dagny Zhu and Mitchell WeikertFri, 08 Dec 2023 - 26min
- 77 - Visionary Viewpoints in Cataract & Refractive Surgery: The Latest on Phacoemulsification With Drs. Dagny Zhu and Elizabeth YeuThu, 30 Nov 2023 - 23min
- 76 - The Retina Radar With Dr. Arshad Khanani: GA With Dr. Peter KaiserThu, 30 Nov 2023 - 25min
- 75 - Visionary Viewpoints in Cataract & Refractive Surgery: Surgical Techniques in Cataract Removal With Drs. Dagny Zhu and William WileyWed, 15 Nov 2023 - 21min
- 74 - Visionary Viewpoints in Cataract & Refractive Surgery: Exploring the Digital Age of Eye Care With Drs. Dagny Zhu and Eric RosenbergTue, 31 Oct 2023 - 32min
- 73 - The Retina Radar With Dr. Arshad Khanani: Gene Therapy With Dr. Dante PieramiciTue, 10 Oct 2023 - 27min
- 72 - The Retina Radar With Dr. Arshad Khanani: Clinical Trials Summit With Dr. Ramin TadayoniTue, 03 Oct 2023 - 23min
- 71 - The Retina Radar With Dr. Arshad Khanani: DR Management With Dr. Christina WengTue, 03 Oct 2023 - 26min
- 70 - The Retina Radar With Dr. Arshad Khanani: nAMD Management With Dr. Margaret ChangFri, 08 Sep 2023 - 28min
- 69 - Long-acting Injectables in RVO Management With Drs. Carl Regillo and Christina WengThu, 15 Jun 2023 - 17min
- 68 - Long-acting Injectables in DME Management With Drs. Carl Regillo and Dilsher DhootThu, 15 Jun 2023 - 18min
- 67 - Long-acting Injectables in nAMD Management With Drs. Carl Regillo and Jennifer LimThu, 15 Jun 2023 - 19min
- 66 - A Practical Roadmap for Diagnosing and Treating DED, With Drs. Lisa Nijm and Vance ThompsonFri, 06 Jan 2023 - 23min
- 65 - Differentiating Current and Emerging Strategies for Managing MGD, With Drs. Lisa Nijm and Stephen PflugfelderWed, 21 Dec 2022 - 22min
- 64 - OSD Cliffs Notes - Fall 2022 Meetings, With Drs. Lisa Nijm and Bennie JengWed, 21 Dec 2022 - 16min
- 63 - Uveitis With Drs. Lejla Vajzovic and Sunil SrivastavaWed, 19 Oct 2022 - 15min
- 62 - Surgery With Drs. Sunil Srivastava and Lejla VajzovicWed, 19 Oct 2022 - 14min
- 61 - Imaging With Drs. Rishi Singh and Sunil SrivastavaWed, 19 Oct 2022 - 16min
- 60 - Retinal Vein Occlusion With Drs. Sunil Srivastava and Rishi SinghWed, 19 Oct 2022 - 19min
- 59 - Neovascular Age-related Macular Degeneration, Dry Age-related Macular Degeneration, and Geographic Atrophy With Drs. Adrienne Scott, Lisa Olmos de Koo, and Rishi SinghWed, 19 Oct 2022 - 26min
- 58 - Diabetic Eye Disease With Drs. Lisa Olmos de Koo and Adrienne ScottWed, 19 Oct 2022 - 15min
- 57 - Targeting Angiopoietin-2 in DME: Efficacy and Safety Data With Drs. Carl Regillo and Nancy Holekamp
The angiopoietin/Tie2 pathway is an attractive therapeutic target for the management of retinal and choroidal vascular diseases, as it has been identified to play a role in vascular permeability and angiogenesis within the eye. Several therapies targeting this pathway have been investigated, and the FDA recently approved the first agent that inhibits both the angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Dual inhibition of these 2 pathways has the potential to enhance visual acuity outcomes while lowering the treatment burden. In this podcast, Dr. Carl Regillo and Dr. Nancy Holekamp discuss the efficacy and safety of therapies targeting Ang-2 in DME.
Tue, 31 May 2022 - 16min - 56 - Targeting Angiopoietin-2 in nAMD: Efficacy and Safety Data With Drs. Carl Regillo and Arshad Khanani
The angiopoietin/Tie2 pathway is an attractive therapeutic target for the management of retinal and choroidal vascular diseases, as it has been identified to play a role in vascular permeability and angiogenesis within the eye. Several therapies targeting this pathway have been investigated, and the FDA recently approved the first agent that inhibits both the angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Dual inhibition of these 2 pathways has the potential to enhance visual acuity outcomes while lowering the treatment burden. In this podcast, Dr. Carl Regillo and Dr. Arshad Khanani discuss the efficacy and safety of therapies targeting Ang-2 in nAMD.
Tue, 31 May 2022 - 20min - 55 - The Tie2 Pathway and Its Role in the Pathophysiology of Retinal Vascular Disease With Drs. Carl Regillo and Judy Kim
The angiopoietin/Tie2 pathway is an attractive therapeutic target for the management of retinal and choroidal vascular diseases, as it has been identified to play a role in vascular permeability and angiogenesis within the eye. Several therapies targeting this pathway have been investigated, and the FDA recently approved the first agent that inhibits both the angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Dual inhibition of these 2 pathways has the potential to enhance visual acuity outcomes while lowering the treatment burden. In this podcast, Dr. Carl Regillo and Dr. Judy Kim discuss the Tie2 pathway and its role in the pathophysiology of retinal vascular diseases.
Tue, 31 May 2022 - 13min - 54 - Retinal Disease Digest: Opportunities for Optometrists Volume 1, Issue 4 Recap with Dr. Steven FerrucciTue, 10 May 2022 - 05min
- 53 - Retinal Disease Digest: Opportunities for Optometrists Volume 1, Issue 3 Recap with Dr. Rishi SinghTue, 10 May 2022 - 04min
- 52 - Retinal Disease Digest: Opportunities for Optometrists Volume 1, Issue 2 Recap with Dr. Steven FerrucciTue, 10 May 2022 - 05min
- 51 - Retinal Disease Digest: Opportunities for Optometrists Volume 1, Issue 1 Recap with Dr. Rishi SinghTue, 10 May 2022 - 04min
- 50 - Multidisciplinary Strategies to Reduce the Burden of Ocular Toxicities in Myeloma With Drs. Sagar Lonial and Asim V. FarooqMon, 31 Jan 2022 - 15min
- 49 - Managing Ocular Toxicities in Patients on Multiple Myeloma Therapy With Drs. Sagar Lonial and Asim V. FarooqMon, 31 Jan 2022 - 16min
- 48 - Frequency and Identification of Ocular Toxicities Associated With Myeloma Therapy With Drs. Sagar Lonial and Bennie JengMon, 31 Jan 2022 - 13min
- 47 - Mechanisms Underlying Ocular Toxicities in Cancer Therapy With Drs. Bennie Jeng and Sagar LonialMon, 31 Jan 2022 - 14min
- 46 - Gel Stent FailureTue, 28 Dec 2021 - 24min
- 45 - Recent Developments in the Role of Optical Coherence Tomography Angiography in the Management of GlaucomaThu, 16 Dec 2021 - 16min
- 44 - Cyclophotocoagulation in Glaucoma: Recent Developments and Best PracticesThu, 16 Dec 2021 - 30min
- 43 - Cerebrospinal Fluid Pressure and GlaucomaThu, 16 Dec 2021 - 24min
- 42 - Management of Glaucoma During the COVID PandemicTue, 09 Nov 2021 - 21min
- 41 - Recap with Dr. Rishi Singh: An Overview of Intravitreal Interventions Volume 10, Issue 4Mon, 27 Sep 2021 - 05min
- 40 - Recap with Dr. Rishi Singh: An Overview of Intravitreal Interventions Volume 10, Issue 3Wed, 18 Aug 2021 - 04min
- 39 - Recap with Dr. Rishi Singh: An Overview of Intravitreal Interventions Volume 10, Issue 2Fri, 30 Jul 2021 - 04min
- 38 - Enhancing Outcomes in OSD Using Combination Therapy and New Drug Formulations, With Drs. Lisa Nijm and John SheppardThu, 29 Jul 2021 - 24min
- 37 - Differentiating New Strategies for Treating OSD: A Look at the Evidence With Drs. Lisa Nijm and Eric DonnenfeldTue, 13 Jul 2021 - 35min
- 36 - Managing Ocular Surface Disease in Special Patient Populations With Drs. Lisa Nijm and Vance Thompson
This educational podcast will review important considerations for the diagnosis and management of ocular surface disease (OSD) in special patient populations. Faculty will provide pearls for preventing and managing OSD in individuals at elevated risk, including those undergoing ocular surgery, those with glaucoma or diabetes, as well as individuals on medications known to disrupt the ocular surface.
Tue, 13 Jul 2021 - 27min - 35 - Recap with Dr. Rishi Singh: An Overview of Intravitreal Interventions, Volume, 10, Issue 1Fri, 09 Jul 2021 - 08min
- 34 - Port Delivery System With Ranibizumab, With Nancy M. Holekamp, MD, and Arshad M. Khanani, MD, MAThu, 01 Jul 2021 - 18min
- 33 - Achieving Vascular Stability through Inhibition of Ang-2 in AMD and DME, With Nancy M. Holekamp, MD, and Carl D. Regillo, MD, FACS
In this podcast, expert clinicians will discuss achieving vascular stability through inhibition of Ang-2.
To obtain CME credit, go here: https://tinyurl.com/y58538ef
Thu, 01 Jul 2021 - 18min - 32 - Emerging Delivery Systems in Neovascular Retinal Disease: Focus on Gene Therapy, With Nancy M. Holekamp, MD, and Arshad M. Khanani, MD, MA
In this podcast, expert clinicians will discuss emerging gene therapies for AMD and DME.
To obtain CME credit, go here: https://tinyurl.com/yusxpn44
Wed, 30 Jun 2021 - 19min - 31 - Emerging Delivery Systems in Neovascular Retinal Disease: Focus on Devices, With Nancy M. Holekamp, MD, and Carl D. Regillo, MD, FACSWed, 30 Jun 2021 - 15min
- 30 - Curbside Consults on Retinal Vein Occlusion Management: Treating RVO Early to Improve Outcomes
Retinal vein occlusions (RVOs) are the second most common retinal vascular disorder after diabetic retinopathy. The early and accurate diagnosis of RVO is paramount so that therapy can be initiated in a timely manner to prevent vision decline. Newer imaging technologies integrated into current diagnostic algorithms are aiding in the diagnosis of RVO and guiding therapy. Further, significant visual and anatomic improvements have been demonstrated with anti-vascular endothelial growth factor (VEGF) therapies in patients with central or branch RVO-related macular edema, and refinement of treatment protocols have the potential to further enhance outcomes as well as reduce treatment burden. In this curbside consult, Drs. Carl Regillo and Christina Weng assess the effect of treating RVO early in its course for the improvement of visual outcomes.
Wed, 02 Jun 2021 - 20min - 29 - Curbside Consults on Retinal Vein Occlusion Management: Use of Imaging in the Diagnosis of RVO
Retinal vein occlusions (RVOs) are the second most common retinal vascular disorder after diabetic retinopathy. The early and accurate diagnosis of RVO is paramount so that therapy can be initiated in a timely manner to prevent vision decline. Newer imaging technologies integrated into current diagnostic algorithms are aiding in the diagnosis of RVO and guiding therapy. Further, significant visual and anatomic improvements have been demonstrated with anti-vascular endothelial growth factor (VEGF) therapies in patients with central or branch RVO-related macular edema, and refinement of treatment protocols have the potential to further enhance outcomes as well as reduce treatment burden. In this curbside consult, Drs. Carl Regillo and Christina Weng discuss the current use of imaging and biomarkers in the diagnosis as well as prognosis of RVO.
Wed, 02 Jun 2021 - 22min - 28 - Curbside Consults on Retinal Vein Occlusion Management: Use of Imaging in Monitoring Treatment Response in RVO
Retinal vein occlusions (RVOs) are the second most common retinal vascular disorder after diabetic retinopathy. The early and accurate diagnosis of RVO is paramount so that therapy can be initiated in a timely manner to prevent vision decline. Newer imaging technologies integrated into current diagnostic algorithms are aiding in the diagnosis of RVO and guiding therapy. Further, significant visual and anatomic improvements have been demonstrated with anti-vascular endothelial growth factor (VEGF) therapies in patients with central or branch RVO-related macular edema, and refinement of treatment protocols have the potential to further enhance outcomes as well as reduce treatment burden. In this curbside consult, Drs. Carl Regillo and David Eichenbaum examine innovations in imaging that can improve the monitoring of treatment response in patients with RVO.
Wed, 02 Jun 2021 - 18min - 27 - Curbside Consults on Retinal Vein Occlusion Management: Deciphering New Data on RVO Treatment – How Do they Affect Real World Practice?
Retinal vein occlusions (RVOs) are the second most common retinal vascular disorder after diabetic retinopathy. The early and accurate diagnosis of RVO is paramount so that therapy can be initiated in a timely manner to prevent vision decline. Newer imaging technologies integrated into current diagnostic algorithms are aiding in the diagnosis of RVO and guiding therapy. Further, significant visual and anatomic improvements have been demonstrated with anti-vascular endothelial growth factor (VEGF) therapies in patients with central or branch RVO-related macular edema, and refinement of treatment protocols have the potential to further enhance outcomes as well as reduce treatment burden. In this curbside consult, Drs. Carl Regillo and David Eichenbaum discuss how advances in the treatment of RVO achieved in clinical trials can be applied to real-world practice.
Wed, 02 Jun 2021 - 10min - 26 - Diagnosing and Managing NMOSD in a Clinical Case With Drs. Prem Subramanian and Andrew LeeFri, 28 May 2021 - 14min
- 25 - Treating NMOSD with an Eye on Prevention With Drs. Prem Subramanian and Patricia CoyleFri, 28 May 2021 - 13min
- 24 - Examining Which Mechanisms of Action Work to Prevent Relapse in NMOSD With Drs. Prem Subramanian and Dean WingerchukFri, 28 May 2021 - 13min
- 23 - Persisting Challenges in NMOSD Diagnosis With Drs. Prem Subramanian and Michael LeeFri, 28 May 2021 - 15min
- 22 - Exploring Treatment Options for Neurotrophic Keratitis: A Challenging CaseMon, 25 Jan 2021 - 14min
- 21 - Staging and Diagnosing Neurotrophic Keratitis: A Challenging CaseMon, 25 Jan 2021 - 13min
- 20 - Exploring Treatment Options for Neurotrophic KeratitisMon, 25 Jan 2021 - 13min
- 19 - Diagnosis and Staging of Neurotrophic KeratitisMon, 25 Jan 2021 - 16min
- 18 - Interpreting the Latest Clinical Trial Results of New and Emerging Treatments for nAMD
Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment regimens have provided significant improvements to long-term visual outcomes in neovascular age-related macular degeneration (nAMD). However, some patients do not receive an optimal response with current anti-VEGF therapies, while poor adherence due to treatment burden remains a significant problem. Continuing advances in the refinement of dosing frequency protocols, as well as the development of therapies and devices that promise to extend dosing intervals, have the potential to overcome treatment burden, further enhancing long-term visual outcomes. In this podcast, Dr. Arshad Khanani and Dr. Peter Kaiser interpret the latest clinical trial data of new and emerging treatments for nAMD.
Transcripts: https://tinyurl.com/Ophthalmology3-4
For CME Credit, click here: https://tinyurl.com/Ophthalmology3-4a
Wed, 29 Jul 2020 - 20min - 17 - Dosing Schedules for Emerging Agents Used to Treat nAMD That Require Less Frequent Dosing Than Standard Anti-VEGF Therapy
Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment regimens have provided significant improvements to long-term visual outcomes in neovascular age-related macular degeneration (nAMD). However, some patients do not receive an optimal response with current anti-VEGF therapies, while poor adherence due to treatment burden remains a significant problem. Continuing advances in the refinement of dosing frequency protocols, as well as the development of therapies and devices that promise to extend dosing intervals, have the potential to overcome treatment burden, further enhancing long-term visual outcomes. In this podcast, Dr. Arshad Khanani and Dr. Nancy Holekamp discuss dosing schedules for emerging agents in the treatment of nAMD that require less frequent dosing than standard anti-VEGF therapies.
Transcription: https://tinyurl.com/Ophthalmology3-3a
For CME Credit, complete activity here: https://tinyurl.com/Ophth3-3a
Wed, 29 Jul 2020 - 17min - 16 - Novel Mechanisms Beyond Anti-VEGF for Treatment of nAMD
Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment regimens have provided significant improvements to long-term visual outcomes in neovascular age-related macular degeneration (nAMD). However, some patients do not receive an optimal response with current anti-VEGF therapies, while poor adherence due to treatment burden remains a significant problem. Continuing advances in the refinement of dosing frequency protocols, as well as the development of therapies and devices that promise to extend dosing intervals, have the potential to overcome treatment burden, further enhancing long-term visual outcomes. In this podcast, Dr. Arshad Khanani and Dr. Peter Kaiser discuss novel mechanisms beyond anti-VEGF for the treatment of nAMD.
Transcription: https://tinyurl.com/Ophthalmology3-2a
For CME Credit, complete activity here: https://tinyurl.com/Ophth3-2a
Wed, 29 Jul 2020 - 16min - 15 - Dosing Schedules for Current Agents Used to Treat Neovascular Age-Related Macular Degeneration (nAMD)
Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment regimens have provided significant improvements to long-term visual outcomes in neovascular age-related macular degeneration (nAMD). However, some patients do not receive an optimal response with current anti-VEGF therapies, while poor adherence due to treatment burden remains a significant problem. Continuing advances in the refinement of dosing frequency protocols, as well as the development of therapies and devices that promise to extend dosing intervals, have the potential to overcome treatment burden, further enhancing long-term visual outcomes. In this podcast, Dr. Arshad Khanani and Dr. Nancy Holekamp discuss dosing schedules for current anti-VEGF agents used in the treatment of nAMD.
Transcript: https://tinyurl.com/Ophthalmology3-1a
For CME credit, complete activity here: https://tinyurl.com/Ophth3-1a
Wed, 29 Jul 2020 - 14min - 14 - Sight-saving Therapeutics for the Treatment of Neovascular Age-Related Macular Degeneration
Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment regimens have provided significant improvements to long-term visual outcomes in neovascular age-related macular degeneration (nAMD). However, some patients do not receive an optimal response with current anti-VEGF therapies, while poor adherence due to treatment burden remains a significant problem. Continuing advances in the refinement of dosing frequency protocols, as well as the development of therapies and devices that promise to extend dosing intervals, have the potential to overcome treatment burden, further enhancing long-term visual outcomes. Within this 4-part podcast series, experts in the field discuss current therapy dosing schedules and their impact on visual outcomes and patient adherence, assess novel mechanisms of action of emerging therapies that have the potential to improve visual acuity, as well as evaluate new and emerging therapeutic and dosing options that have the potential to reduce treatment burden in patients with nAMD.
Transcription: https://tinyurl.com/Ophthalmology3
Wed, 29 Jul 2020 - 13 - Effect of Subretinal Fluid on Visual Outcomes in Neovascular AMD
The integration of intravitreal anti-vascular endothelial growth factor therapies into treatment algorithms for the management of neovascular retinal diseases has provided significant visual outcome gains for these patients. The effectiveness of current treatment algorithms varies based on treatment protocol, number of therapy injections, and patient adherence. However, suboptimal responses to therapy along with loss of patient adherence from treatment burden has defined a need for the development of novel treatments and sustained delivery options for the management of neovascular retinal diseases. In this podcast, Dr. Carl Regillo and Dr. Dante Pieramici discuss the effect of subretinal fluid on visual outcomes in neovascular age-related macular degeneration.
Mon, 29 Jun 2020 - 14min - 12 - Sustained Suppression of VEGF – What is the Effect? Where is the Evidence?
The integration of intravitreal anti-vascular endothelial growth factor therapies into treatment algorithms for the management of neovascular retinal diseases has provided significant visual outcome gains for these patients. The effectiveness of current treatment algorithms varies based on treatment protocol, number of therapy injections, and patient adherence. However, suboptimal responses to therapy along with loss of patient adherence from treatment burden has defined a need for the development of novel treatments and sustained delivery options for the management of neovascular retinal diseases. In this podcast, Dr. Carl Regillo and Dr. Dante Pieramici discuss the potential effects of sustained vascular endothelial growth factor inhibition in neovascular retinal disease.
Mon, 29 Jun 2020 - 16min - 11 - Effective Treatment Interval Extensions in Neovascular Retinal Disease
The integration of intravitreal anti-vascular endothelial growth factor therapies into treatment algorithms for the management of neovascular retinal diseases has provided significant visual outcome gains for these patients. The effectiveness of current treatment algorithms varies based on treatment protocol, number of therapy injections, and patient adherence. However, suboptimal responses to therapy along with loss of patient adherence from treatment burden has defined a need for the development of novel treatments and sustained delivery options for the management of neovascular retinal diseases. In this podcast, Dr. Carl Regillo and Dr. Charles Wykoff discuss effective treatment interval extensions in neovascular retinal disease.
Mon, 29 Jun 2020 - 14min - 10 - Inhibition of Ang-2: Potential Effect in DME Treatment Paradigms
The integration of intravitreal anti-vascular endothelial growth factor therapies into treatment algorithms for the management of neovascular retinal diseases has provided significant visual outcome gains for these patients. The effectiveness of current treatment algorithms varies based on treatment protocol, number of therapy injections, and patient adherence. However, suboptimal responses to therapy along with loss of patient adherence from treatment burden has defined a need for the development of novel treatments and sustained delivery options for the management of neovascular retinal diseases. In this podcast, Dr. Carl Regillo and Dr. Jeffrey Heier discuss inhibition of angiopoietin-2 and its potential effect on current treatment paradigms for the management of diabetic macular edema.
Mon, 29 Jun 2020 - 14min - 9 - Inhibition of Ang-2: Potential Effect in AMD Treatment Paradigms
The integration of intravitreal anti-vascular endothelial growth factor therapies into treatment algorithms for the management of neovascular retinal diseases has provided significant visual outcome gains for these patients. The effectiveness of current treatment algorithms varies based on treatment protocol, number of therapy injections, and patient adherence. However, suboptimal responses to therapy along with loss of patient adherence from treatment burden has defined a need for the development of novel treatments and sustained delivery options for the management of neovascular retinal diseases. In this podcast, Dr. Carl Regillo and Dr. Jeffrey Heier discuss inhibition of angiopoietin-2 and its potential effect on current treatment paradigms for the management of neovascular age-related macular degeneration.
Mon, 29 Jun 2020 - 13min - 8 - Drug Delivery Systems in Neovascular Retinal Disease
The integration of intravitreal anti-vascular endothelial growth factor therapies into treatment algorithms for the management of neovascular retinal diseases has provided significant visual outcome gains for these patients. The effectiveness of current treatment algorithms varies based on treatment protocol, number of therapy injections, and patient adherence. However, suboptimal responses to therapy along with loss of patient adherence from treatment burden has defined a need for the development of novel treatments and sustained delivery options for the management of neovascular retinal diseases. In this podcast, Dr. Carl Regillo and Dr. Charles Wykoff discuss emerging drug delivery systems for the management of neovascular retinal disease.
Mon, 29 Jun 2020 - 15min - 7 - Targeting Treatment in Neovascular Retinal Disease
In this MedEdTalks micro-CE podcast, Rishi P. Singh, MD, and Arshad M. Khanani, MD, MA, discuss new findings about emerging therapies that target the angiopoietin/Tie2 pathway that may improve the treatment of neovascular retinal diseases.
Transcript: https://bit.ly/38jWicU
To obtain CME Credit, please go here: https://bit.ly/2nBqmhq
Sun, 29 Sep 2019 - 13min - 6 - Drug Delivery in Neovascular Retinal DiseaseSun, 29 Sep 2019 - 16min
- 5 - Dosing Strategies in nAMD – Real World Applications
In this MedEdTalks micro-CE podcast, Rishi P. Singh, MD, and Nathan C. Steinle, MD, discuss dosing strategies in patients with neovascular age-related macular degeneration (AMD) to help improve patient outcomes.
Transcript: https://bit.ly/2DZw9SC
To obtain CME credit, please go here: https://bit.ly/2ombOmh
Sun, 29 Sep 2019 - 12min - 4 - Treatment Burden in nAMD – How to Address with Patients
In this MedEdTalks micro-CE podcast, Rishi P. Singh, MD, and Theodore Leng MD, MS, discuss the burden of treatment on patients with neovascular age-related macular degeneration (AMD) and strategies for overcoming barriers to treatment.
Transcript: https://bit.ly/2YB3q0e
To obtain CME Credit, please go here: https://bit.ly/2ojxBec
Sun, 29 Sep 2019 - 14min - 3 - Treatment Burden in nAMD – How to Address Barriers in Care
In this MedEdTalks micro-CE podcast, Rishi P. Singh, MD, and Dilsher S. Dhoot, MD, discuss current barriers to care of patients with neovascular age-related macular degeneration (AMD) and other management considerations for providers.
Transcript: https://bit.ly/2RL41uX
To obtain CME Credit, please go here: https://bit.ly/2mJfo9s
Sun, 29 Sep 2019 - 10min - 2 - Anti-VEGF Use in Diabetic Retinopathy – Current Insights
In this MedEdTalks micro-CE podcast, Rishi P. Singh, MD, and Andrew A. Moshfeghi, MD, MBA, will discuss current insights and the evidence-based use of anti-vascular epithelial growth factor (VEGF) in diabetic retinopathy.
Transcript: https://bit.ly/3542h3r
To obtain CME credit, please go here: https://bit.ly/2ojW0QQ
Sun, 29 Sep 2019 - 14min - 1 - Optimizing Outcomes in Neovascular Retinal Diseases through Targeted Dosing, Treatment, and Delivery
In this podcast series Dr. Rishi Singh will be talking with:
Dr. Andrew Moshfeghi on Current Insights into Anti-VEGF use in Diabetic Retinopathy; Dr. Dilsher Dhoot on how to address the treatment burden in nAMD as a provider; Dr. Ted Leng on how to address the treatment burden in nAMD with patients; Dr. Nathan Steinle on real world applications for dosing strategies in nAMD; Dr. Nancy Holekamp on drug delivery in neovascular retinal disease; and with Dr. Arshad Khanani on targeting treatment in neovascular retinal diseaseWe encourage you to take 12 to 15 minutes out of your day to hear these updates on neovascular retinal diseases
Thu, 26 Sep 2019 - 01min
Podcasts ähnlich wie MedEdTalks - Ophthalmology
- Global News Podcast BBC World Service
- El Partidazo de COPE COPE
- Herrera en COPE COPE
- The Dan Bongino Show Cumulus Podcast Network | Dan Bongino
- Es la Mañana de Federico esRadio
- La Noche de Dieter esRadio
- Hondelatte Raconte - Christophe Hondelatte Europe 1
- Curiosidades de la Historia National Geographic National Geographic España
- Dateline NBC NBC News
- 財經一路發 News98
- La rosa de los vientos OndaCero
- Más de uno OndaCero
- La Zanzara Radio 24
- L'Heure Du Crime RTL
- El Larguero SER Podcast
- Nadie Sabe Nada SER Podcast
- SER Historia SER Podcast
- Todo Concostrina SER Podcast
- 安住紳一郎の日曜天国 TBS RADIO
- アンガールズのジャンピン[オールナイトニッポンPODCAST] ニッポン放送
- 辛坊治郎 ズーム そこまで言うか! ニッポン放送
- 飯田浩司のOK! Cozy up! Podcast ニッポン放送
- 吳淡如人生實用商學院 吳淡如
- 武田鉄矢・今朝の三枚おろし 文化放送PodcastQR